Psychopharmacological Treatment of Autism

Blankenship, Kelly; Erickson, Craig A.; Stigler, Kimberly A.; Posey, David J.; McDougle, Christopher J.

doi:10.1093/med/9780195371826.003.0077

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One reason why the idea of a fractionable triad was potentially revelatory was because it provided a new and possibly more tractable way to approach the understanding of the causes, as well as the management, of ASD. Despite almost half a century of research into all aspects of ASD, there are still no reliable diagnostic biomarkers for ASD, and nor do we know enough about how to remediate the core features of the disorder either through medication (see Blankenship et al, 2011), as Rutter notes in his commentary, or through behavioural interventions (e.g. Green et al, 2010).…”

mentioning

confidence: 99%

Autism spectrum disorder: Fractionable or coherent?

Williams¹,

Bowler²

2013

Autism

View full text Add to dashboard Cite

mentioning

confidence: 99%

Autism spectrum disorder: Fractionable or coherent?

Williams¹,

Bowler²

2013

Autism

View full text Add to dashboard Cite

“…Several other medications have been studied so far targeting the core social relating impairments in ASD [ 97 ]. These include memantine [ 98 , 99 ], amantadine [ 100 ], D-cycloserine [ 101 , 102 ], lamotrigine [ 103 ], secretin [ 104 , 105 ], and naltrexone [ 106 – 109 ].…”

Section: Psychiatric Treatment Of Associated Challenging Behaviorsmentioning

confidence: 99%

Assessment and Treatment in Autism Spectrum Disorders: A Focus on Genetics and Psychiatry

Butler

Youngs

Roberts

et al. 2012

Autism Research and Treatment

View full text Add to dashboard Cite

Autism spectrum disorders (ASDs) are neurobehavioral disorders characterized by abnormalities in three behavioral domains including social interaction, impaired communication, and repetitive stereotypic behaviors. ASD affects approximately 1% of children and is on the rise with significant genetic mechanisms underlying these disorders. We review the current understanding of the role of genetic and metabolic factors contributing to ASD with the use of new genetic technology. Fifty percent is diagnosed with chromosomal abnormalities, small DNA deletions/duplications, single-gene conditions, or metabolic disturbances. Genetic evaluation is discussed along with psychiatric treatment and approaches for selection of medication to treat associated challenging behaviors or comorbidities seen in ASD. We emphasize the importance of prioritizing treatment based on target symptom clusters and in what order for individuals with ASD, as the treatment may vary from patient to patient.

show abstract

“…In recent years, the rates of ASD have escalated, with the most recent Centers for Disease Control and Prevention data estimating prevalence at 1 in 68 children in the USA [ 2 ]. While some successful pharmacological and behavioral interventions have been identified for the treatment of hyperactivity/inattention and irritability associated with ASD [ 3 , 4 ], little progress has been made in the effective treatment of primary social and communication deficits. The limited success of clinical trials targeting core social impairment in ASD is likely in part due to the heterogeneity of ASD, difficulty quantitatively tracking treatment response, and high placebo response rates [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders

et al. 2016

Self Cite

View full text Add to dashboard Cite

BackgroundResearchers have demonstrated that d-cycloserine (DCS) can enhance the effects of behavioral interventions in adults with anxiety and enhances prosocial behavior in animal models of autism spectrum disorders (ASD). This study extended upon this background by combining DCS with behavioral social skills therapy in youth with ASD to assess its impact on the core social deficits of ASD. We hypothesized that DCS used in combination with social skills training would enhance the acquisition of social skills in children with ASD.MethodsA 10-week, double-blind, placebo-controlled trial of DCS (50 mg) given 30 min prior to weekly group social skills training was conducted at two sites. Children with ASD were randomized to receive 10 weeks (10 doses) of DCS or placebo in a 1:1 ratio.ResultsNo statistically significant difference attributable to drug treatment was observed in the change scores for the primary outcome measure, the Social Responsiveness Scale (SRS), total score (p = 0.45), or on secondary outcome measures.ConclusionsThe results of this trial demonstrated no drug-related short-term improvement on the primary outcome measure, or any of the secondary outcome measures. However, an overall significant improvement in SRS total raw score was observed from baseline to end of treatment for the entire group of children with ASD. This suggests a need to further study the efficacy of the social skills training protocol. Limitations to the current study and areas for future research are discussed.Trial registrationClinicalTrials.govNCT01086475

show abstract

Psychopharmacological Treatment of Autism

Cited by 5 publications

References 0 publications

Autism spectrum disorder: Fractionable or coherent?

Autism spectrum disorder: Fractionable or coherent?

Assessment and Treatment in Autism Spectrum Disorders: A Focus on Genetics and Psychiatry

A randomized, placebo-controlled trial of d-cycloserine for the enhancement of social skills training in autism spectrum disorders

Contact Info

Product

Resources

About